Nuvation Bio (NUVB) is in focus after second quarter 2026 results showed revenue of US$31.69 million and a net loss of US$62.84 million, as well as upcoming IBTROZI trial data presentations.

The share price sits at US$6.10 after a 1 day share price return that declined 4.98%. However, a 90 day share price return of 41.20% and a 1 year total shareholder return of 121.01% suggest momentum has been building around Nuvation Bio, as revenue trends and IBTROZI data updates keep attention on the stock despite a weaker year to date share price return.

If you are looking beyond a single biotech story, now is a useful moment to see what else is moving in healthcare and review the 44 healthcare AI stocks

After a share price that has already climbed sharply over the past year, the key tension for Nuvation Bio now is simple. Is most of the upside already reflected, or does the current valuation still leave meaningful headroom?

Most Popular Narrative: 69% Undervalued

The most followed narrative on Nuvation Bio pegs fair value at about $19.70, well above the recent $6.10 share price, and anchors that gap in IBTROZI and Safusidenib expectations.

IBTROZI is rapidly emerging as the preferred therapy in ROS1 positive non small cell lung cancer, with best in class durability, strong brain penetration and growing first line use. This positions the drug to drive sustained prescription growth and expanding recurring revenue over many years.

Want to understand why this narrative supports such a big gap to today’s price? It hinges on aggressive revenue expansion, sharply higher profit margins and a rich future earnings multiple that assumes Nuvation Bio matures into a much larger, cash generative oncology platform.

Result: Fair Value of $19.70 (UNDERVALUED)

However, this bullish Nuvation Bio story depends on key swing factors, including execution on IBTROZI global expansion and progress in the long duration safusidenib glioma trial.

Another View on Nuvation Bio’s Valuation

The bullish narrative paints Nuvation Bio as heavily undervalued, yet the current P/S ratio of 12.6x is higher than both peers at 11.4x and the US Pharmaceuticals industry at 5x. Even if this is close to a 13.5x fair ratio, how comfortable are you paying above sector levels today?

For a closer look at what this pricing gap could mean in practice, take a look at the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Given the strong views on Nuvation Bio already in play, it makes sense to move quickly and stress test the data yourself. Start by weighing those potential upsides in the 2 key rewards

Looking for more investment ideas beyond Nuvation Bio?

If Nuvation Bio has your attention, now is the right time to broaden your watchlist using a few focused stock ideas that many investors overlook.

• Target reliable cash generators by reviewing companies in the 11 dividend fortresses for potential income focused opportunities.
• Spot potential mispricings early by scanning the 51 high quality undervalued stocks for stocks where fundamentals and current prices appear out of step.
• Strengthen your core portfolio by checking the solid balance sheet and fundamentals stocks screener (49 results) for businesses with sturdier financial foundations that may handle setbacks more effectively.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.